Asoprisnil: Endometriosis therapy treatment of uterine fibroids selective progesterone receptor modulator

Drugs of the Future

Volumn 30, Issue 10, 2005, Pages 985-991

  Cole, P ^a   Castaner J ^a   Fernandez Forner D ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASOPRISNIL; ESTROGEN; MIFEPRISTONE; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR;

ABDOMINAL PAIN; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSMENORRHEA; ENDOMETRIOSIS; ENDOMETRIUM; ESTROGEN RELEASE; HEADACHE; HUMAN; LUTEOLYSIS; METRORRHAGIA; NAUSEA; NIDATION; NONHUMAN; PELVIS PAIN SYNDROME; UTERUS MYOMA;

EID: 30744461830     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.10.945144     Document Type: Article

References (29)

1. Schubert, G., Kaufmann, G., Sobeck, L., Oettel, M., Elger, W., Kurischko, A. (Jenapharm GmbH). 11-Benza Idoximeestradiene-derivates, a process for their preparation and pharmaceutical compositions containing them. CA 2130516, DE 4322283, EP 0648778.
2. Schubert, G., Ring, S., Erhart, B., Müller, G. (Jenapharm GmbH). Method for the production of 4-(17alpha-methyl substituted 3-oxoestra-4 9-dien-11beta-yl)benzaldehyd-(1E or 1Z)-oximes. DE 10056675, EP 1339733, JP 2004513178, US 2004063172, WO 2002038581.
3. Schubert, G., Ring, S., Erhart, B. (Jenapharm GmbH). Method for the production of 4-(17alpha substituted 3-oxoestra-4,9-dien-11beta-yl) benzaldehyd-(1E or 1Z)-oximes. CA 2427632, DE 10056676, EP 1339734, JP 2004513179, US 2004053905, WO 2002038582.
4. Chwalisz, K., Perrez, M.C., DeManno, D., Winkel, C., Schubert, G., Elger, W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Rev 2005, 26: 423-38.
5. Chabbert-Buffet, N., Meduri, G., Bouchard, P., Spitz, I.M. Selective progesterone receptor modulators and progesterone antagonists: Mechanisms of action and clinical applications. Hum Reprod Update 2004, 11: 293-307.
6. Misrahi, M., Atger, M., d'Auriol, L., Loosfelt, H., Meriel, C., Fridlansky, F., Guiochon-Mantel, A., Galibert, F., Milgrom, E. Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun 1987, 143: 740-8.
7. Girish, C., Jayanthi, M., Sivaraman, G. Asoprisnil: A selective progesterone receptor modulator. Indian J Pharmacol 2005, 37: 266-7.
8. Sitruk-Ware, R. Pharmacological profile of progestins. Maturitas 2004, 47: 277-83.
9. Marshall, L.M., Spiegelman, D., Barbieri, R.L., Goldman, M.B., Manson, J.E., Colditz, G.A., Willette, W.C., Hunter, D.J. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997, 90: 967-73.
10. Myers, E.R., Barber, M.D., Gustilo-Ashby, T., Couchman, G., Matchar, D.B., McCrory, D.C. Management of uterine leiomyomata: What do we really know? Obstet Gynecol 2002, 100: 8-17.
11. Brandon, D.D., Bethea, C.L., Strawn, E.Y., Novy, M.J., Burry, K.A., Harrington, M.S., Erickson, T.E., Warner, C., Keenan, E.J., Clinton, G.M. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993, 169: 78-85.
12. Winkel, C.A. Evaluation and management of women with endometriosis. Obstet Gynecol 2003, 102: 397-408.
13. Schubert, G., Elger, W., Kaufmann, G., Schneider, B., Reddersen, G., Chwalisz, K. Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11β-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin Reprod Med 2005, 23: 58-73.
14. Schubert, G., Kaufmann, G., Elger, W., Sobek, L., Oettel, M. Synthesis of 11beta-benzaldoxime estra-4,9-dien-3-one derivatives with dissociated antiprogestin activity. 14th Int Symp Med Chem (Sept 8-12, Maastricht) 1996, Abst P-3.19.
15. Schering AG Annual Report 2004.
16. DeManno, D., Elger, W., Garg, R., Lee, R., Schneider, B., Hess-Stumpp, H., Schubert, G., Chwalisz, K. Asoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy. Steroids 2003, 68: 1019-32.
17. Elger, W., Bartley, J., Schneider, B., Kaufmann, G., Schubert, G., Chwalisz, K. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000, 65: 713-23.
18. Elger, W., Ivell, R., Nandy, A., Rasch, A., Triller, A., Chwalisz, K. Modulation of uterine prostaglandin secretion by the selective progesterone receptor modulator (SPRM) asoprisnil, progestins, and antiprogestins in cycling and ovariectomized guinea pigs. Fertil Steril 2004, 82(Suppl. 2): Abst P-509.
19. Melvin, V.M.S., Perez, M., Chwalisz, K., Edwards, D.P. Mechanism of action of the selective progesterone receptor modulator asoprisnil. 87th Annu Meet Endocr Soc (June 4-7, San Diego) 2005, Abst P3-284.
20. Maruo, T., Matsuo, H., Samoto, T., Shimomura, Y, Kurachi, O., Nakago, S., Yamada, T., Xu, Q., Chen, W., Wang, J., Ohara, N. Control of uterine leiomyoma cell proliferation and apoptosis by progesterone and selective progesterone receptor modulator. 3rd Int Conf Female Reprod Tract (May 27-30, Frauenchiemsee) 2005.
21. Velagaleti, P., Liu, J., Premkumar, N., Bopp, B., Lee, R., Mulford, D. Interspecies comparison of absorption and excretion following intravenous or oral administration of [14C]J867 to rats, mice and monkeys. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 10-14, Toronto) 2002, Abst M1283.
22. Bilyeu, T.A., Morris, E.M., Lee, R., Premkumar, N.D., Cole, K.C., Velagaleti, P.R., Bopp, B.A., Castagnoli, N., Mulford, D. Interspecies comparison: In vitro metabolism of J856 by hepatocytes and microsomes from male and female human, and various animal species. Drug Metab Rev 2002, 34: 46.
23. Morris, E.M., Beltey, K., Premkumar, N., Velagaleti, P., Bopp, B., Castagnoli, N., Lee, R., Mulford, D. Interspecies comparison of the metabolism of J867 following intravenous or oral administration to male and female bile duct-cannulated rats and mice. Drug Metab Rev 2002, 34: 73.
24. Chwalisz, K., Elger, W., Stickler, T, Mattia-Goldberg, C., Larsen, L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005, 20: 1090-9.
25. Lee, R.D., Edmonds, A., Chwalisz, K., Vernillet, I. Effect of asoprisnil, a novel selective progesterone receptor modulator, on the QT interval in healthy female subjects. 34th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 11-13, Rockville) 2005, Abst 68.
26. Chwalisz, K., DeManno, D., Garg, R., Larsen, L., Mattia-Goldberg, C., Stickler, T. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med 2004, 22: 113-9.
27. Chwalisz, K., Larsen, L., Edmonds, A., Winkel, C. Effectiveness of asoprisnil, a selective progesterone receptor modulator (SPRM), in treating uterine leiomyomata. Adv Uterine Leiomyoma Res: 2nd NIH Int Congr (Feb 24-25, Bethesda) 2005, Abst.
28. Chwalisz, K., Lamar Parker, R., Williamson, S., Larsen, L., McCrary, K., Elger, W. Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867. J Soc Gynecol Invest 2003, 10(2, Suppl.): Abst 636.
29. Chwalisz, K., Mattia-Goldberg, C., Lee, M., Elger, W., Edmonds, A. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril 2004, 82(Suppl. 2): Abst O-207.